Clinical Trial Update: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) [Phase 2]

View source ↗

Summary

This entry reports a Phase 2 clinical trial evaluating Tedopi combined with either docetaxel or nivolumab as second-line therapy for metastatic non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Tedopi
• nivolumab (nivolumab)

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING